Actively Recruiting
CANF-Comb-II PET-MR in Atherosclerosis Multisite
Led by Washington University School of Medicine · Updated on 2026-03-23
80
Participants Needed
2
Research Sites
218 weeks
Total Duration
On this page
Sponsors
W
Washington University School of Medicine
Lead Sponsor
C
Cedars-Sinai Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to learn more about plaque biology in asymptomatic carotid artery stenosis (ACAS) patients through imaging. The main questions it aims to answer are: * To determine the ability of 64Cu-CANF-Comb positron emission tomography (PET) to risk stratify ACAS patients for stroke event, to include transient ischemic attack or remote ipsilateral intervention. * To further understand the role of Natriuretic Peptide Receptor C (NPRC) in the evolution of carotid atherosclerosis. Participants will be asked to undergo a carotid PET-magnetic resonance imaging (MRI) examination to assess whether the carotid atherosclerosis uptake of 64Cu-CANF-Comb as measured by PET-MRI correlates with patient outcomes (stroke, transient ischemic attack, or remote ipsilateral intervention).
CONDITIONS
Official Title
CANF-Comb-II PET-MR in Atherosclerosis Multisite
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults, 18 years of age or older
- Diagnosed with asymptomatic carotid artery stenosis showing 60% diameter stenosis by ultrasound or other imaging
- Planned treatment with optimal medical therapy alone or with carotid endarterectomy by treating surgeon
You will not qualify if you...
- Unable to consent or sign informed consent
- Unstable clinical condition preventing study participation
- Unable to tolerate up to 60 minutes lying on back with arms at sides for PET-MR imaging
- Prior carotid endarterectomy or stent on the same side
- History of transient ischemic attack or stroke within the past 6 months
- Unwilling or unable to comply with study procedures or follow-up
- Contraindications to MRI (e.g., pacemaker, brain aneurysm clips, shrapnel, claustrophobia)
- Currently pregnant or breastfeeding; females of childbearing potential must have a negative pregnancy test within 24 hours before tracer injection or be post-menopausal or have had surgical menopause
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Cedars Sinai Medical Center
Los Angeles, California, United States, 90048
Actively Recruiting
2
Washington University in St. Louis
St Louis, Missouri, United States, 63130-2344
Actively Recruiting
Research Team
M
Molly Mohrman
CONTACT
P
Pamela Woodard, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here